Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $11.0 million.

  • Vivos Therapeutics' Shares Outstanding (Weighted Average) rose 6573.03% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 6573.03%. This contributed to the annual value of $5.0 million for FY2024, which is 31167.49% up from last year.
  • As of Q3 2025, Vivos Therapeutics' Shares Outstanding (Weighted Average) stood at $11.0 million, which was up 6573.03% from $9.1 million recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $21.2 billion for Q4 2021, and its period low was $849446.0 during Q3 2022.
  • For the 5-year period, Vivos Therapeutics' Shares Outstanding (Weighted Average) averaged around $3.3 billion, with its median value being $6.6 million (2024).
  • Per our database at Business Quant, Vivos Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 16574323.56% in 2021 and then crashed by 9999.59% in 2022.
  • Over the past 5 years, Vivos Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $21.2 billion in 2021, then tumbled by 100.0% to $920592.0 in 2022, then soared by 32.46% to $1.2 million in 2023, then skyrocketed by 311.67% to $5.0 million in 2024, then surged by 118.4% to $11.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $11.0 million in Q3 2025, compared to $9.1 million in Q2 2025 and $8.6 million in Q1 2025.